Urinary neopterin: A novel biomarker of disease progression in amyotrophic lateral sclerosis.
ALS
biomarker
disease progression
pharmacodynamic
proinflammatory
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
30
11
2021
accepted:
23
12
2021
pubmed:
31
12
2021
medline:
5
4
2022
entrez:
30
12
2021
Statut:
ppublish
Résumé
The aim was to evaluate urinary neopterin, a marker of pro-inflammatory state, as a potential biomarker of disease prognosis and progression in amyotrophic lateral sclerosis (ALS); and to compare its utility to urinary neurotrophin receptor p75 extracellular domain (p75 This was an observational study including 21 healthy controls and 46 people with ALS, 29 of whom were sampled longitudinally. Neopterin and p75 At baseline, urinary neopterin was higher in ALS compared to controls (181.7 ± 78.9 μmol/mol creatinine vs. 120.4 ± 60.8 μmol/mol creatinine, p = 0.002, Welch's t test) and correlated with the Revised ALS Functional Rating Scale (r = -0.36, p = 0.01). Combining previously published urinary p75 Urinary neopterin holds promise as marker of disease progression in ALS and is worthy of future evaluation for its potential to predict response to anti-inflammatory therapies.
Sections du résumé
BACKGROUND AND PURPOSE
The aim was to evaluate urinary neopterin, a marker of pro-inflammatory state, as a potential biomarker of disease prognosis and progression in amyotrophic lateral sclerosis (ALS); and to compare its utility to urinary neurotrophin receptor p75 extracellular domain (p75
METHODS
This was an observational study including 21 healthy controls and 46 people with ALS, 29 of whom were sampled longitudinally. Neopterin and p75
RESULTS
At baseline, urinary neopterin was higher in ALS compared to controls (181.7 ± 78.9 μmol/mol creatinine vs. 120.4 ± 60.8 μmol/mol creatinine, p = 0.002, Welch's t test) and correlated with the Revised ALS Functional Rating Scale (r = -0.36, p = 0.01). Combining previously published urinary p75
CONCLUSION
Urinary neopterin holds promise as marker of disease progression in ALS and is worthy of future evaluation for its potential to predict response to anti-inflammatory therapies.
Identifiants
pubmed: 34967083
doi: 10.1111/ene.15237
pmc: PMC8901536
mid: NIHMS1767701
doi:
Substances chimiques
Biomarkers
0
Neopterin
670-65-5
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
990-999Subventions
Organisme : NINDS NIH HHS
ID : U54 NS092091
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Motor Neurone Disease Association
ID : MALASPINA/APR13/817-791
Pays : United Kingdom
Organisme : NINDS NIH HHS
ID : U01 NS107027
Pays : United States
Organisme : Motor Neurone Disease Association
ID : TURNER/OCT15/972-797
Pays : United Kingdom
Informations de copyright
© 2021 European Academy of Neurology.
Références
Int Arch Occup Environ Health. 1996;68(6):387-8
pubmed: 8891772
J Neurol. 2020 Dec;267(12):3609-3616
pubmed: 32638112
Exp Neurol. 2012 Sep;237(1):147-52
pubmed: 22735487
Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9
pubmed: 11464847
Neurol Neuroimmunol Neuroinflamm. 2015 Apr 09;2(3):e100
pubmed: 25884010
Intern Med. 1999 Feb;38(2):133-9
pubmed: 10225668
Muscle Nerve. 2016 Feb;53(2):169-82
pubmed: 26574709
Proteomics Clin Appl. 2010 Apr;4(4):464-78
pubmed: 21137064
Exp Neurol. 2020 Jun;328:113259
pubmed: 32105709
Neurol Neuroimmunol Neuroinflamm. 2016 Jun 01;3(4):e244
pubmed: 27308305
JAMA Neurol. 2017 Jun 1;74(6):677-685
pubmed: 28437540
Brain Behav. 2017 Feb 19;7(3):e00637
pubmed: 28293476
Amyotroph Lateral Scler Frontotemporal Degener. 2019 Nov;20(7-8):595-604
pubmed: 31284774
Neurology. 2017 Mar 21;88(12):1137-1143
pubmed: 28228570
J Exp Med. 1984 Jul 1;160(1):310-6
pubmed: 6429267
PLoS One. 2013 Dec 18;8(12):e83237
pubmed: 24367586
Nat Rev Neurol. 2021 Jun;17(6):333-348
pubmed: 33927394
Clin Proteomics. 2013 Dec 02;10(1):19
pubmed: 24295388
J Clin Pharm Ther. 2001 Oct;26(5):319-29
pubmed: 11679022
J Neurol Neurosurg Psychiatry. 2019 Dec;90(12):1338-1346
pubmed: 31175169
PLoS Med. 2007 Oct 16;4(10):e296
pubmed: 17941714
Neurology. 2006 Jan 24;66(2):265-7
pubmed: 16434671
Sci Rep. 2020 Oct 26;10(1):18291
pubmed: 33106568
Sci Rep. 2017 Aug 22;7(1):9094
pubmed: 28831083
J Neurol Neurosurg Psychiatry. 2018 Mar;89(3):239-247
pubmed: 29142138
Ann Neurol. 2018 Feb;83(2):258-268
pubmed: 29331073
Muscle Nerve. 2020 Aug;62(2):156-166
pubmed: 31899540
Neurology. 2020 Jul 7;95(1):e59-e69
pubmed: 32385188
Glia. 2010 Jan 15;58(2):231-43
pubmed: 19672969
Eur J Med. 1993 Jun-Jul;2(6):327-32
pubmed: 8252177
Ann Clin Transl Neurol. 2020 Jul;7(7):1103-1116
pubmed: 32515902
Anal Chim Acta. 2016 Jul 13;927:72-81
pubmed: 27237839
EMBO J. 2018 Aug 15;37(16):
pubmed: 29875132
Clin Vaccine Immunol. 2011 Feb;18(2):318-26
pubmed: 21159926
Eur J Neurol. 2009 Jun;16(6):771-4
pubmed: 19236470
Clin Chem Lab Med. 2000 Apr;38(4):345-53
pubmed: 10928656
Free Radic Biol Med. 2018 Feb 1;115:371-382
pubmed: 29198726
Nat Neurosci. 2007 May;10(5):615-22
pubmed: 17435755
Glia. 2013 Mar;61(3):409-19
pubmed: 23281114
J Neuroinflammation. 2020 Aug 6;17(1):232
pubmed: 32762702
PLoS One. 2012;7(6):e39216
pubmed: 22720079
Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):569-73
pubmed: 1309947
Muscle Nerve. 2019 Jan;59(1):23-33
pubmed: 29979478
Curr Drug Metab. 2002 Apr;3(2):175-87
pubmed: 12003349
Front Immunol. 2019 Dec 13;10:2759
pubmed: 31921102
Clin Chem. 1987 Jan;33(1):62-6
pubmed: 3802497
J Neurol Neurosurg Psychiatry. 2020 Apr;91(4):350-358
pubmed: 31937582
Int Immunol. 2015 Mar;27(3):117-29
pubmed: 25344935
Cytokine. 2019 Nov;123:154768
pubmed: 31276936
N Engl J Med. 2020 Jul 9;383(2):109-119
pubmed: 32640130
J Neurol Sci. 2015 Jan 15;348(1-2):245-50
pubmed: 25563799
Am J Clin Pathol. 1989 Oct;92(4):415-23
pubmed: 2552791